Navigation Links
Radiation Control Technologies, Inc. Announces Exclusive License to Two Patents from the National Institutes of Health
Date:7/30/2012

ROCKVILLE, Md., July 30, 2012 /PRNewswire/ -- Radiation Control Technologies, Inc. (RCTI), a private development stage biopharmaceutical company developing RCT1938, a novel radiosensitizer that sensitizes tumor cells to killing by radiation while protecting healthy cells from radiation damage by inhibiting the synthesis of the novel target protein CD47, announced today that it has been granted an exclusive license to two patents from the National Institutes of Health (NIH).  The NIH exclusive license covers composition and uses of RCT1938 worldwide as a radiosensitizer to treat cancer and to treat or prevent radiation exposure in humans.

Radiation Control Technologies is entering into advanced preclinical testing of RCT1938 as an adjuvant for radiotherapy, as well as seeking federal grants and contracts to develop RCT1938 as radiation medical countermeasure.  RCT1938 promises to be a safe and effective adjuvant for radiotherapy for cancer and a promising medical countermeasure for acute radiation sickness and delayed effects of acute radiation exposure.  RCT1938 is derived from a chemical class that has been proven safe in clinical trials.

CD47, the novel target protein, is a "master switch" controlling key molecular pathways in tumor regression and radioprotection post-ionizing radiation.  By blocking the synthesis and expression of CD47, RCT1938 selectively sensitizes solid tumors to radiation killing and inhibits apoptosis (programmed cell death) in a comprehensive, multifactorial manner in healthy tissues.  More importantly, RCT1938 simultaneously activates natural survival pathways and triggers the cellular switch from apoptosis to survival in radiation injury in healthy cells.

Craig Liddell, Ph.D., CEO & President of RCTI, said, "Being awarded the NIH license is a key milestone for our company.  We believe RCT1938 will become the standard adjuvant for use in conjunction with cancer radiotherapy.  It is believed that the compound will permit lower doses of radiation to be effective and allow for higher lifetime doses of radiation with greater patient safety and fewer side effects."

"Our initial lead indication is head and neck cancer, and we believe this will be just the beginning in oncology, with RCT1938 expected to have a therapeutic role in the more than 50% of cancer patients currently treated with radiation," concluded Dr. Liddell.

AboutRadiation Control Technologies, Inc: RCTI was founded in 2011 to commercialize a top 10 scientific discovery recognized by the NIH in 2010 for the novel role of CD47 in radiosensitization of tumors cells and radioprotection of healthy cells.  RCTI was founded by a co-inventor of the licensed NIH patents, Jeffrey S. Isenberg, MD, Chair of the Scientific Advisory Board.  RCTI has assembled an experienced team of drug developers and business professionals led by CEO & President, Dr. Craig M. Liddell.

Company contact:
Dr. Craig M. Liddell
Radiation Control Technologies, Inc.
703-795-7622
cliddell@radiationcontroltechnologies.com

Media Contact:
Tiberend Strategic Advisors, Inc.
Claire Sojda
212-827-0020
csojda@tiberend.com


'/>"/>
SOURCE Radiation Control Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. West Physics Consulting Teams with Mirion Technologies Dosimetry Services Division to Deliver Radiation Detection Services
2. Fujitsu to Showcase Radiation-Hardened RFID Using FRAM Technology at Interphex 2012 in New York City, Booth #2430
3. Global Ablation Technologies Market (2011-2016) - By Application and Devices in Radiofrequency, Cryoablation, Microwave, Ultrasound, Hydrothermal, Radiation, Electrical, Light/Laser and Hydromechanical - Global Trends & Competitive Analysis
4. Avaxia Biologics is Awarded U.S. Patent for Method to Treat Radiation Damage to the Digestive Tract and Mucositis Caused by Radiation
5. ViewRay Receives FDA 510(k) Clearance for MRI-Guided Radiation Therapy System
6. Elektas Gamma Knife and Radiation Therapy Systems for Cancer Treatment Take Top Three Places in 2012s Best in KLAS for Radiation Therapy
7. Radiation Therapy in Oncology Drug Pipeline Update 2012
8. The Best Radiation Therapy Solution just got Better
9. Landauer, Inc. Appoints Peter Cempellin To President Of Landauer Radiation Measurement
10. Elekta to Showcase Revolutionary Agility Beam-shaping Innovation at Radiation Physics Annual Meeting
11. Ablation Devices Market to 2016 - (Radiofrequency, Cryoablation, Microwave, Ultrasound, Hydrothermal, Radiation, Cardiac, Cancer and Gynecology) - Global Market Forecast and Trends Analysis by Technology, Devices & Applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)...  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... . ... ... ... Astellas ...
(Date:6/23/2016)... -- Guerbet announced today that it has been named a ... One of 12 suppliers to receive the ... of Premier members through exceptional local customer service and ... lower costs. "We ... customer service from Premier," says Massimo Carrara , ...
(Date:6/23/2016)... , June 23, 2016 ... "Surgical Procedure Volumes: Global Analysis (United States, China, ... Canada)" report to their offering. ... essential tool for healthcare business planners, provides surgical procedure ... at surgery trends with an in-depth analysis of growth ...
Breaking Medicine Technology:
(Date:6/24/2016)... , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway ... call for a minimum wage raise to $12 an hour by 2020 and then adjusting ... restore the lost value of the minimum wage, assure the wage floor does not erode ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB ... Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards ... in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With ...
(Date:6/24/2016)... Las Vegas, Nevada (PRWEB) , ... June 24, ... ... their Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and ... The Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm ... sciences executive with extensive sequencing and genomics experience, as Vice President of North American ... Hill will be responsible for leading the sales team in the commercialization of the ...
(Date:6/24/2016)... ... 24, 2016 , ... Today, MTI-GlobalStem, a provider of optimized ... difficult to transfect cells, announces its launch of the PluriQ™ G9™ Gene Editing ... is a complete system for culturing and transfecting human pluripotent stem cells ...
Breaking Medicine News(10 mins):